Physician profile
Pauline Ahn
NPI 1043742885
$1,342.96
in general payments reported to CMS, 2019-2025
13 companies · $368 in 2025
The $368 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.97 · 2022: $274 · 2023: $245 · 2024: $360 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $379.98 | 2021-2025 | Vaxneuvance, Vaxelis, Enflonsia |
| Genzyme Corporation | $254.65 | 2023-2025 | |
| Glaxosmithkline, LLC. | $157.96 | 2021-2024 | Pediarix, Bexsero |
| Pfizer INC. | $139.05 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $120.60 | 2024 | Koselugo |
| Takeda Pharmaceuticals U.S.A., INC. | $68.11 | 2021-2024 | Vpriv |
| Kaleo, INC. | $61.30 | 2022-2024 | Auvi-Q |
| Supernus Pharmaceuticals, INC. | $35.79 | 2022 | |
| Sobi, INC | $30.69 | 2023 | |
| Alk-Abello, INC | $28.86 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $25.16 | 2024 | Flumist Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $21.66 | 2025 | Neffy |
| Cipher Pharmaceuticals US LLC | $19.15 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.